Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search
Recent Press Releases

XORTX Announces Change to Board of Directors

  • August 28, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, Aug. 28, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased announce that Ian Klassen will join the XORTX board of directors effective immediately. 


› Read more
Recent Press Releases

XORTX Appoints Dr. David Sans in New York as Director Corporate Development

  • August 7, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David Sans as Director, Corporate Development to be based in New York City. 


› Read more
Recent Press Releases

XORTX Partners with Mount Sinai’s Icahn School of Medicine on US-based Clinical Trial in COVID-19

  • August 4, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a partnership with the Icahn School of Medicine at Mount Sinai, New York to study the incidence of Acute Kidney Injury and Hyperuricemia in patients hospitalized with COVID-19.


› Read more
Recent Press Releases

XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors

  • June 23, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, June 23, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Mr. Anthony J. Giovinazzo will become a Special Advisor to the CEO and the Board of Directors.


› Read more
Recent Press Releases

XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs

  • May 19, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, May 19, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease, is pleased to provide the following update on its clinical stage programs to treat chronic autosomal dominant polycystic kidney disease (ADPKD) – XRx-008 and acute kidney injury (AKI) associated with COVID-19 Infection – XRx-101.


› Read more
Recent Press Releases

XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

  • April 30, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, April 30, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted the manufacturing contract for the active pharmaceutical ingredient for XRx-101 (Oxypurinol) and XRx-008 to Lonza Pharma & Biotech (“Lonza”). 


› Read more
Recent Press Releases

XORTX Provides Overview and Update of Key Activities

  • April 30, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, April 30, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial statements and related management’s discussion and analysis for the year ended December 31, 2019.


› Read more
Recent Press Releases

XORTX Announces New Clinical Advisory Board Member

  • March 26, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, March 26, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat polycystic kidney disease (PKD), is pleased to announce that Dr.


› Read more
Recent Press Releases

XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury…

  • March 16, 2020December 22, 2020
  • by aaronbb

CALGARY, Alberta, March 16, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late stage clinical programs, is re-issuing its earlier press release with a clarified title pursuant to the Company’s announcement that it is exploring the potential of using XRx-101 (a new formulation of Oxypurinol) as a novel treatment for acute kidney and lung injury accompanying Coronavirus infection and specifically for the COVID-19 infection.


› Read more
Recent Press Releases

XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection

  • March 16, 2020December 22, 2020
  • by aaronbb

• XRx-101 – a triple action approach to suppressing COVID-19 Injury •

CALGARY, Alberta, March 16, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late stage clinical programs, announces that it is exploring the potential of using XRx-101 (a new formulation of Oxypurinol) as a novel treatment for acute kidney and lung injury accompanying Coronavirus infection and specifically for the COVID-19 infection.


› Read more

Posts navigation

1 2 3 4 5 6

Press Releases

  • XORTX Announces Notice to Grant European Patent April 6, 2021
  • XORTX to Present at “Zoom With LD MICRO” March 16, 2021
  • XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021 March 9, 2021
  • XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection March 8, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress